Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 106.

Journal Article

Baues, C., Marnitz, S., Engert, A., Baus, W., Jablonska, K., Fogliata, A., Vasquez-Torres, A., Scorsetti, M. and Cozzi, L. (2017). Proton versus Photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation. Strahlenther. Onkol., 193. S. S5 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Baues, C., Semrau, R., Gaipl, U. S., Broeckelmann, P. J., Rosenbrock, J., Engert, A. and Marnitz, S. (2017). Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma. Strahlenther. Onkol., 193 (2). S. 95 - 100. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Behringer, K., Goergen, H., Borchmann, P., Diehl, V., Fuchs, M., Lohri, A., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., Topp, M. S., Soekler, M., Mathas, S., Meissner, J., von Tresckow, B., Boell, B. and Engert, A. (2014). IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., Halbsguth, T., Eichenauer, D. A., Fuchs, M., Reiners, K. S., Renno, J. H., van der Ven, K., Kuehr, M., von Wolff, M., Diehl, V., Engert, A. and Borchmann, P. (2020). Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial (vol 23, pg 1818, 2012). Ann. Oncol., 31 (8). S. 1093 - 1094. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., Ott, H. W., Hofer, S., Pluetschow, A., Diehl, V., Engert, A. and Borchmann, P. (2010). No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann. Oncol., 21 (10). S. 2052 - 2061. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Boell, B., Pluetschow, A., Eichenauer, D., von Tresckow, B., Atta, J., Pfreundschuh, M., Michaela, F. B., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2015). GERMAN HODGKIN STUDY GROUP PHASE I TRIAL OF DOXORUBICIN, VINBLASTINE, DACARBAZINE, AND LENALIDOMIDE (AVD-REV) FOR ELDERLY HODGKIN LYMPHOMA PATIENTS-FINAL ANALYSIS. Haematologica, 100. S. 322 - 323. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Boell, B., Pluetschow, A., Eichenauer, D. A., Thielen, I, von Tresckow, B., Atta, J., Pfreundschuh, M., Feuring-Buske, M., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2014). German Hodgkin Study Group Phase I trial of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) for elderly Hodgkin Lymphoma patients. Oncol. Res. Treat., 37. S. 12 - 13. BASEL: KARGER. ISSN 2296-5262

Boesl, T., Hansen, H. P., Engert, A. and von Strandmann, E. Pogge (2016). HODGKIN CELL-DERIVED EXTRACELLULAR VESICLES SHAPE FIBROBLAST ACTIVITY. Haematologica, 101. S. 2 - 4. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, P., Eichenauer, D., Pluetschow, A., Kreissl, S., Fuchs, M., Soekler, M., Engel, N., Mathas, S., Behringer, K., Kobe, C., Dietlein, M., Diehl, V. and Engert, A. (2014). TARGETED BEACOPP VARIANTS IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS OF A RANDOMIZED PHASE II STUDY. Haematologica, 99. S. 497 - 499. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M. and Engert, A. (2017). TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 24 - 26. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Borchmann, S., Goergen, H., Sasse, S., Kreissl, S., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Diehl, V. and Engert, A. (2018). Pretreatment vitamin D deficiency is associated with lower progression free and overall survival in prospectively treated Hodgkin lymphoma. Oncol. Res. Treat., 41. S. 273 - 275. BASEL: KARGER. ISSN 2296-5262

Borchmann, S., Hude, I., Sasse, S., Broeckelmann, P., von Tresckow, B., Momotow, J. and Engert, A. (2017). Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors. Oncol. Res. Treat., 40. S. 142 - 144. BASEL: KARGER. ISSN 2296-5262

Borchmann, S., Mueller, H. and Engert, A. (2016). A COMPREHENSIVE ANALYSIS OF HODGKIN LYMPHOMA SEASONALITY ACROSS VARIOUS GEOGRAPHIC REGIONS. Haematologica, 101. S. 31 - 33. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, S., Mueller, H. and Engert, A. (2016). A comprehensive analysis of seasonality patterns of incidence and mortality in Hodgkin lymphoma across geographic regions. Oncol. Res. Treat., 39. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262

Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M., Borchmann, P. and Engert, A. (2016). OSTEONECROSIS AFTER TREATMENT FOR HODGKIN LYMPHOMA: THE GERMAN HODGKIN STUDY GROUP EXPERIENCE. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M. and Engert, A. (2016). OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG). Haematologica, 101. S. 5 - 7. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Borchmann, S., Mueller, H., Hude, I, Fuchs, M., Borchmann, P. and Engert, A. (2019). Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann. Oncol., 30 (8). S. 1329 - 1335. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289

Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289

Broeckelmann, P. J., Goergen, H., Fuchs, M., Eich, H. T., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2016). Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: Experience of the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 39. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262

Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 46 - 48. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 320 - 321. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Broeckelmann, P. J., Goergen, H., Pluetschow, A., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS. Haematologica, 101. S. 4 - 5. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Broeckelmann, P. J., Mueller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., McCall, S. J., Morschhauser, F., Fuchs, M., Borchmann, P., Moskowitz, C. H. and Engert, A. (2017). Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol., 28 (6). S. 1352 - 1359. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Broeckelmann, P. J., Mueller, H., Kuecueksarioglan, E., Engert, A. and von Tresckow, B. (2017). DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 146 - 147. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT-ASSOCIATED BURDEN AND SIDE EFFECTS. Haematologica, 101. S. 146 - 148. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P. J., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HL SURVIVORS ON TREATMENT-ASSOCIATED BURDENS AND SIDE EFFECTS. Haematologica, 101. S. 61 - 62. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cavcic, M., Oschlies, I., Fuchs, M., Engert, A. and Klapper, W. (2017). Recovery of paraffin blocks and central archiving. Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma. Pathologe, 38 (6). S. 529 - 535. NEW YORK: SPRINGER. ISSN 1432-1963

Cohen, J. B., Engert, A., Ansell, S. M., Younes, A., Trneny, M., Savage, K. J., Ramchandren, R., Collins, G. P., Fanale, M. A., Armand, P., Zinzani, P. L., de Boer, J. P., Shipp, M. A., Santoro, A., Timmerman, J. M., Sacchi, M., Sy, O. and Kuruvilla, J. (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study. Br. J. Haematol., 181. S. 87 - 89. HOBOKEN: WILEY. ISSN 1365-2141

Deckert, M., Engert, A., Brueck, W., Ferreri, A. J. M., Finke, J., Illerhaus, G., Klapper, W., Korfel, A., Kueppers, R., Maarouf, M., Montesinos-Rongen, M., Paulus, W., Schlegel, U., Lassmann, H., Wiestler, O. D., Siebert, R. and DeAngelis, L. M. (2011). Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia, 25 (12). S. 1797 - 1808. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924

Eich, H. T., Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Pluetschow, A., Fuchs, M., Engert, A. and Baues, C. (2016). FINAL RESULTS OF A QUALITY ASSURANCE PROGRAM WITHIN THE GERMAN HODGKIN STUDY GROUP HD13/14 TRIAL - A REPORT FROM THE RADIOTHERAPY REFERENCE PANEL INTEGRATING MODERN GUIDELINES. Haematologica, 101. S. 14 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Eich, H. T., Kriz, J., Klimm, B., Sasse, S., Goergen, H., Diehl, V., Borchmann, P., Mueller, R. and Engert, A. (2012). Involved-field (IF) Versus Extended-field (EF) Radiation Therapy (RT) for Patients in Early Unfavorable Stages of Hodgkin Lymphoma: 10-year Update of the HD8 Trial of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys., 84 (3). S. S70 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0360-3016

Eich, H. T., Kriz, J., Reinartz, G., Kobe, C., Kuhnert, G., Haverkamp, U., Haverkamp, H., Hegerfeld, K., Baues, C. and Engert, A. (2013). Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys., 87 (2). S. S5 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Eichenauer, D. A., Aleman, B. M. P., Andre, M., Federico, M., Hutchings, M., Illidge, T., Engert, A. and Ladetto, M. (2018). Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 29. S. 19 - 30. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Eichenauer, D. A., Engert, A., Andre, M., Federico, M., Illidge, T., Hutchings, M. and Ladetto, M. (2014). Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 25. S. 70 - 76. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Eichenauer, D. A., Engert, A. and Dreyling, M. (2011). Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 22. S. vi55 - 4. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Eichenauer, D. A., Goergen, H., Pluetschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Broeckelmann, P. J., Fuchs, M., Boell, B., von Tresckow, B., Borchmann, P. and Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30 (6). S. 1425 - 1429. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Eichenauer, D. A., Kreissl, S., Buehnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., Hartmann, S., von Tresckow, B., Engert, A. and Borchmann, P. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann. Oncol., 32 (6). S. 807 - 811. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Eichenauer, D. A., Kreissl, S., Buehnen, I., Goergen, H., Hartmann, S., Fuchs, M., von Tresckow, B., Engert, A. and Borchmann, P. (2020). PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 87 - 89. BASEL: KARGER. ISSN 2296-5262

Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Borchmann, P. and Engert, A. (2017). Long-term outcome of patients with early-stage nodular lymphocyte-predominant hodgkin lymphoma (NLPHL) treated within the randomized HD7, HD10 and HD13 trials: An analysis from the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 40. S. 142 - 143. BASEL: KARGER. ISSN 2296-5262

Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Diehl, V., Borchmann, P. and Engert, A. (2017). LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 82 - 83. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924

Engert, A. (2018). Implementing PD-1 antibodies in the treatment of patients with Hodgkin lymphoma. Oncol. Res. Treat., 41. S. 227 - 229. BASEL: KARGER. ISSN 2296-5262

Engert, A., Domingo Domenech, E., Rueda, A., Armand, P., Trneny, M., Feldman, T., Ansell, S., Provencio, M., Jaeger, U., Cohen, J. B., Savage, K. J., Willenbacher, W., Sacchi, M., Sumbul, A. and Ramchandren, R. (2018). Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study. Oncol. Res. Treat., 41. S. 273 - 274. BASEL: KARGER. ISSN 2296-5262

Engert, A., Eich, H. and Hoeffken, K. (2022). Hodgkin lymphoma The paradigm for the success of interdisciplinary clinical trials. Onkologie, 28 (10). S. 842 - 845. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Engert, A., Eich, H. T. and Hoffken, K. (2018). Hodgkin's Lymphoma - new Horizons. Onkologe, 24 (4). S. 278 - 280. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J., Collins, G., Ramchandren, R., Cohen, J., De Boer, J. P., Kuruvilla, J., Savage, K., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL. Haematologica, 102. S. 145 - 146. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Engert, A., Hirji, I., Taylor, F., Bennett, B., Cocks, K., Kato, K. and Cella, D. (2016). QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB MONOTHERAPY IN CHECKMATE 205 (COHORT B), A PHASE 2 STUDY. Haematologica, 101. S. 73 - 74. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Engert, A. and Hoeffken, K. (2014). Hodgkin-Lymphom A Track Record. Onkologe, 20 (5). S. 418 - 419. NEW YORK: SPRINGER. ISSN 1433-0415

Engert, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J., Collins, G., Savage, K., Trneny, M., Kato, K., Farsaci, B., Parker, S., Rodig, S. and Younes, A. (2016). CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Ferdinandus, J., Oertel, M., Eichenauer, D. A., Meissner, J., Engert, A. and Borchmann, P. (2022). Advanced-stage Hodgkin lymphoma. Onkologie, 28 (10). S. 889 - 901. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. -G, Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). Final analysis of a randomized phase II trial with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma -PVAG-14 pilot-. Oncol. Res. Treat., 37. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262

Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. G., Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Gillessen, S., Pluetschow, A., Fuchs, M., Markova, J., Greil, R., Topp, M., Meissner, J., Zijlstra, J., Eichenauer, D., Broeckelmann, P., Diehl, V., Borchmann, P., Engert, A. and von Tresckow, B. (2020). Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 88 - 90. BASEL: KARGER. ISSN 2296-5262

Hartmann, T., Huebel, K., Monsef, I, Engert, A. and Skoetz, N. (2015). Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for malignant lymphoma or multiple myeloma patients: A systematic review with meta-analysis. Oncol. Res. Treat., 38. S. 71 - 72. BASEL: KARGER. ISSN 2296-5262

Hay, A. E., Klimm, B., Chen, B. E., Goergen, H., Shepherd, L. E., Fuchs, M., Gospodarowicz, M. K., Borchmann, P., Connors, J. M., Markova, J., Crump, M., Lohri, A., Winter, J. N., Doerken, B., Pearcey, R. G., Diehl, V., Horning, S. J., Eich, H. T., Engert, A. and Meyer, R. M. (2013). An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann. Oncol., 24 (12). S. 3065 - 3070. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Herbrecht, R., Cernohous, P., Engert, A., Le Gouill, S., Macdonald, D., Machida, C., Myint, H., Saleh, A., Singer, J., Wilhelm, M. and van der Jagt, R. (2013). Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann. Oncol., 24 (10). S. 2618 - 2624. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534

Hude, I., Mueller, H., Goergen, H., Buerkle, C., Behringer, K., Diehl, V., Engert, A. and Borchmann, P. (2016). LONGITUDINAL EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN HODGKIN LYMPHOMA PATIENTS AND SURVIVORS: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hude, I., Sasse, S., Broeckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A. and Borchmann, S. (2017). BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION. Haematologica, 102. S. 460 - 461. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hutzschenreuter, F., Kreuzer, K. -A, Monsef, L., Engert, A. and Skoetz, N. (2015). Granulocyte and granulocyte-macrophage colony stimulating factors for patients with myelodysplastic syndromes: systematic review with meta-analysis. Oncol. Res. Treat., 38. S. 184 - 186. BASEL: KARGER. ISSN 2296-5262

Jaeger, U., Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncol. Res. Treat., 40. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262

Jakob, T., Follmann, M., Borchmann, P., Baues, C., Sasse, S., Broeckelmann, P. J., Kreissl, S., Eichenauer, D., von Tresckow, B., Buerkle, C., Engert, A. and Skoetz, N. (2018). Guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients. Oncol. Res. Treat., 41. S. 17 - 18. BASEL: KARGER. ISSN 2296-5262

Klimm, B., Goergen, H., Fuchs, M., von Tresckow, B., Boell, B., Meissner, J., Glunz, A., Diehl, V., Eich, H. T., Engert, A. and Borchmann, P. (2013). Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann. Oncol., 24 (12). S. 3070 - 3077. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kobe, C., Dietlein, M., Borchmann, P., Engert, A., Kuhnert, G., Fuchs, M., Haverkamp, H., Eich, H. T., Kriz, J. and Diehl, V. (2011). PET-Response Adapted Therapy in Hodgkin Lymphoma. Eur. J. Cancer, 47. S. S16 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049

Kobe, C., Goergen, H., Fuchs, M., Eich, H. T., Baues, C., Diehl, V., Kuhnert, G., Drzezga, A., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S312 - 1. NEW YORK: SPRINGER. ISSN 1619-7089

Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407

Kreissl, S., Eichenauer, D. A., Meissner, J., Topp, M. S., Engert, A. and Borchmann, P. (2018). New developments in the treatment of advanced classical Hodgkin's lymphoma. Onkologe, 24 (4). S. 315 - 322. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Kreissl, S., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Huettmann, A., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup. Oncol. Res. Treat., 40. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262

Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfart, K., Lukas, P., Pluetschow, A., Schmidberger, H., Staar, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). Quality control of involved field radiotherapy in the HD 13 and HD 14 trials. Strahlenther. Onkol., 193 (2). S. 109 - 116. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Baues, C., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Marnitz-Schulze, S., Fuchs, M., Engert, A. and Eich, H. T. (2017). New quality assurance program integrating modern radiotherapy within the German Hodgkin Study Group. Strahlenther. Onkol., 193 (2). S. 100 - 109. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Baues, C., Oertel, M., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Marnitz-Schulze, S., Schmidberger, H., Vordermark, D., Haverkamp, U., Engert, A. and Eich, H. (2018). First Results of Quality Control of Involved Node Radiotherapy within the HD17-Study of the German Hodgkin Study Group (GHSG). Strahlenther. Onkol., 194. S. S14 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Engert, A. and Eich, H. (2015). Establishment of a new Quality Assurance Program in Age of modern Radiotherapy as Part of the German Hodgkin Study Group. Strahlenther. Onkol., 191. S. S165 - 1. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K. K., Lukas, P., Schmidberger, H., Staar, S., Engert, A. and Eich, H. (2015). Establishing a New Quality Assurance Program of Modern Radiation Therapy Within the German Hodgkin Study Group. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E454 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Kriz, J., Mueller, R. -P., Mueller, H., Kuhnert, G., Engert, A., Kobe, C., Haverkamp, U. and Eich, H. T. (2012). Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma Is the definition on the basis of a chest radiograph in the era of CT obsolete? Strahlenther. Onkol., 188 (11). S. 1020 - 1025. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Analysis of the Quality Assurance Program of the Involved Field Radiotherapy within the HD13 and HD14 Study the German Hodgkin Study Group. Strahlenther. Onkol., 191. S. S10 - 2. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K. K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E449 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Marschner, J-P, Treder, M., Kohrt, H. E., Topp, M. S. and Engert, A. (2016). AFM13, a novel bispecific (CD30xCD16A) tetravalent antibody (TandAb (R)) specifically engaging NK-cells to fight Hodgkin Lymphoma (HL). Oncol. Res. Treat., 39. S. 28 - 29. BASEL: KARGER. ISSN 2296-5262

Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262

Oertel, M., Elsayad, K., Engenhart-Cabillic, R., Reinartz, G., Baues, C., Schmidberger, H., Vordermark, D., Marnitz, S., Lukas, P., Ruebe, C., Engert, A., Lenz, G. and Eich, H. T. (2020). Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. Strahlenther. Onkol., 196 (12). S. 1096 - 1103. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Rancea, M., Skoetz, N., Trelle, S., da Costa, B. R., Engert, A., Fischer, K., Hallek, M. and Eichhorst, B. (2014). FIRST-LINE TREATMENT STRATEGIES FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY RESULTS OF A NETWORK META-ANALYSIS. Haematologica, 99. S. 58 - 59. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Rancea, M., von Tresckow, B., Monsef, I, Engert, A. and Skoetz, N. (2014). The role of high-dose chemotherapy followed by autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma: a systematic review with meta-analysis. Oncol. Res. Treat., 37. S. 147 - 148. BASEL: KARGER. ISSN 2296-5262

Rosenbrock, J., Goergen, H., Semrau, R., Nast-Kolb, B., Celik, E., Morgenthaler, J., Assenmacher, K., Houbois, C., Engert, A., Baues, C. and Marnitz, S. (2017). Volumetric assessment of mediastinal masses in Hodgkin Lymphoma - leaving history behind and approaching the truth. Strahlenther. Onkol., 193. S. S127 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Sasse, S., Behringer, K., Semrau, R. and Engert, A. (2014). Controversies in the treatment of early and intermediate stage Hodgkin's lymphoma. Onkologe, 20 (5). S. 448 - 455. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Sasse, S., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2018). Treatment of early stage Hodgkin lymphoma. Discussion of current trials and treatment recommendations. Onkologe, 24 (4). S. 303 - 315. NEW YORK: SPRINGER. ISSN 1433-0415

Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL. Haematologica, 101. S. 12 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL. Haematologica, 101. S. 13 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Sasse, S., Klimm, B., Goergen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., Koch, O., Wilhelm, M., Trenn, G., Finke, J., Mueller, R. P., Diehl, V., Eich, H. T., Borchmann, P. and Engert, A. (2012). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann. Oncol., 23 (11). S. 2953 - 2960. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534

Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2022). Treatment of early stage favorable and unfavorable Hodgkin lymphoma. Onkologie, 28 (10). S. 879 - 889. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Sasse, S., Momotow, J. and Engert, A. (2020). Checkpoint inhibitors in Hodgkin lymphoma. Internist, 61 (7). S. 660 - 669. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Sickinger, M. T., von Tresckow, B., Kobe, C., Engert, A., Borchmann, P. and Skoetz, N. (2014). PET-ADAPTED TREATMENT MODIFICATION IN EARLY STAGE HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Haematologica, 99. S. 399 - 400. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Skoetz, N., Bergenthal, N., Will, A., Streckmann, F., Elter, T. and Engert, A. (2014). Physical exercise improves fatigue in patients with haematological malignancies: a Cochrane systematic review and meta-analysis. Oncol. Res. Treat., 37. S. 277 - 278. BASEL: KARGER. ISSN 2296-5262

Skoetz, N., Bergenthal, N., Will, A., Streckmann, F., Monsef, I., Wolkewitz, K. D., Elter, T. and Engert, A. (2014). AEROBIC PHYSICAL EXERCISE FOR PATIENTS WITH HAEMTOLOGICAL MALIGNANCIES. A SYSTEMATIC REVIEW AND META-ANALYSIS. Haematologica, 99. S. 517 - 518. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Skoetz, N., Blank, O., Buetikofer, L., Monsef, I., Engert, A. and Vehreschild, J. J. (2016). ANTIBIOTICS VERSUS G-CSFS VERSUS A COMBINATION OF BOTH TO PREVENT INFECTIOUS COMPLICATIONS AND DEATHS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: PRELIMINARY RESULTS OF A NETWORK META-ANALYSIS. Haematologica, 101. S. 484 - 486. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Skoetz, N., Rancea, M., Trelle, S., Nueesch, E., Engert, A. and Kreuzer, K. A. (2015). COMPARISON OF TYROSINE-KINASE INHIBITORS AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA: RESULTS OF A NETWORK META-ANALYSIS INCLUDING 6314 PATIENTS. Haematologica, 100. S. 433 - 434. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Sud, A., Thomsen, H., Law, P., Foersti, A., da Silva Filho, M. I., Holroyd, A., Broderick, P., Orlando, G., Lenive, O., Wright, L., Cooke, R., Easton, D., Pharoah, P., Dunning, A., Peto, J., Canzian, F., Eeles, R., Kote-Jarai, Z., Muir, K., Pashayan, N., Consortium, P., Hoffmann, P., Noethen, M., Joeckel, K. -H., von Strandmann, E. P., Lightfoot, T., Kane, E., Roman, E., Lake, A., Jarrett, R., Swerdlow, A., Orr, N., Engert, A., Hemminki, K. and Houlston, R. (2017). GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY. Haematologica, 102. S. 91 - 92. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Thurner, L., Hartmann, S., Kemele, M., Fadle, N., Regitz, E., Kim, Y. -J., Bohle, R. M., Nimmesgern, A., von Mueller, L., Schneider, N., Vornanen, M., Sundstroem, C., de Leval, L., Fuchs, M., Engert, A., Kempf, V. A. J., Kueppers, R., Preuss, K. D., Hansmann, M. -L. and Pfreundschuh, M. (2017). The role of Moraxella in the pathogenesis of IgD(+) nodular lymphocyte predominant Hodgkin lymphoma. Oncol. Res. Treat., 40. S. 143 - 144. BASEL: KARGER. ISSN 2296-5262

Voltin, C., Stockter, S., Baues, C., Fuchs, M., Dietlein, M., Mettler, J., Engert, A., Borchmann, P., Drzezga, A. and Kobe, C. (2017). Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of F-18-FDG PET? Eur. J. Nucl. Med. Mol. Imaging, 44. S. S244 - 2. NEW YORK: SPRINGER. ISSN 1619-7089

Voltin, C. -A., Goergen, H., Baues, C., Fuchs, M., Mettler, J., Kreissl, S., Oertl, J., Klaeser, B., Moccia, A., Drzezga, A., Engert, A., Borchmann, P., Dietlein, M. and Kobe, C. (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann. Oncol., 29 (9). S. 1926 - 1932. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Walewski, J., Hellmann, A., Siritanaratkul, N., Ozsan, G. H., Ozcan, M., Chuncharunee, S., Goh, A. S., Jurczak, W., Koren, J., Wang, B., Singh, S., Huebner, D. and Engert, A. (2016). SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY. Haematologica, 101. S. 56 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Wilhelm, M., Smetak, M., Reimer, P., Geissinger, E., Ruediger, T., Metzner, B., Schmitz, N., Engert, A., Schaefer-Eckart, K. and Birkmann, J. (2016). First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385

Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P. -L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J. and Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann. Oncol., 28 (7). S. 1436 - 1448. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Zinzani, P. L., Engert, A., Younes, A., Santoro, A., Ansell, S., Timmerman, J., Collins, G., Armand, P., Savage, K. J., Trneny, M., Fanale, M., Kuruvilla, J., Cohen, J. B., Shipp, M., Rodig, S., Kato, K., Sumbul, A., Farsaci, B. A. and Ratanatharathorn, V. (2016). CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Haematologica, 101. S. 43 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

von Tresckow, B. and Engert, A. (2014). Brentuximab vedotin. A new targeted approach for the treatment of relapsed or refractory Hodgkin's lymphoma patients. Onkologe, 20 (5). S. 464 - 470. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

von Tresckow, B., Goebeler, M. E., Sayehli, C., Gundermann, S., Eichenauer, D., Aulitzky, W., Bacchus, L., Igel, S., Schwab, M., Sasse, S., Hauns, B., Mais, A., Hentsch, B., Kohlhof, H., Krauss, R., Krauss, B., Baumgartner, R., Vitt, D. and Engert, A. (2014). FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY). Haematologica, 99. S. 711 - 712. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

von Tresckow, B., Kreissl, S., Haverkamp, H., Sasse, S., Diehl, V., Engert, A. and Borchmann, P. (2016). BEACOPP-ESCALATED FOLLOWED BY RADIOTHERAPY OF INITIAL BULK OR RESIDUAL DISEASE IN ADVANCED-STAGE HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GHSG HD9 AND HD12 TRIALS. Haematologica, 101. S. 18 - 19. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

This list was generated on Fri Mar 29 10:07:23 2024 CET.